Department of Pediatrics (General Pediatrics), Stanford University School of Medicine, Stanford, CA, USA.
Stanford Children's Health/Lucile Packard Children's Hospital, Stanford, 725 Welch Road, MC 5906, Palo Alto, CA, 94304, USA.
Pediatr Nephrol. 2018 Nov;33(11):2193-2199. doi: 10.1007/s00467-018-4010-7. Epub 2018 Jul 9.
Though acute kidney injury (AKI) is often multifactorial, investigators are now emphasizing the specific contribution of nephrotoxins. This study examines the epidemiology of nephrotoxin exposure and nephrotoxin-associated AKI among children undergoing congenital heart surgery (CHS).
This is a retrospective cohort study of children admitted following CHS between June 1, 2014, and September 30, 2014. Nephrotoxins were defined according to the Nephrotoxic Injury Negated by Just-in-time-Action (NINJA) collaborative; high nephrotoxin exposure was defined as receipt of ≥ 3 nephrotoxins concurrently. AKI was diagnosed according to KDIGO creatinine criteria. Severe AKI was defined as KDIGO stage ≥ 2. Poisson models were used to compute adjusted relative risk (aRR) of high nephrotoxin exposure for AKI.
One hundred fifty-four children (median age 20.4 months, IQR 2.3-59.5) were included. One hundred thirty-one (85.1%) received at least one nephrotoxin; 32 (20.8%) received ≥ 3 nephrotoxins. The most commonly administered medications were ketorolac (n = 74, 48.1%), aspirin (n = 62, 40.3%), ibuprofen (n = 51, 33.1%), vancomycin (n = 39, 25.3%), piperacillin/tazobactam (n = 35, 22.7%), and enalapril (n = 14, 9.1%). AKI occurred more commonly in those exposed to ≥ 3 nephrotoxins (62.5 vs. 50.8%); this was not statistically significant after adjusting for confounders (aRR = 1.2, 95% CI 0.9-1.7). Severe AKI was similar between those with and without high nephrotoxin exposure (21.9 vs. 19.7%, p = 0.78).
Nephrotoxin use is common following pediatric CHS. While we found no association between high nephrotoxin exposure and AKI, this may be related to the multifactorial nature of AKI in this population. For many common nephrotoxins, less injurious agents exist and nephrotoxin exposure may represent a modifiable risk factor for AKI.
尽管急性肾损伤(AKI)通常是多因素的,但研究人员现在强调了肾毒素的具体贡献。本研究检查了接受先天性心脏手术(CHS)的儿童中肾毒素暴露和肾毒素相关性 AKI 的流行病学。
这是一项回顾性队列研究,纳入了 2014 年 6 月 1 日至 9 月 30 日期间接受 CHS 后的儿童。肾毒素根据肾毒性损伤通过即时行动否定(NINJA)协作来定义;高肾毒素暴露定义为同时接受≥3 种肾毒素。AKI 根据 KDIGO 肌酐标准诊断。严重 AKI 定义为 KDIGO 分期≥2。泊松模型用于计算高肾毒素暴露与 AKI 的调整相对风险(aRR)。
共纳入 154 名儿童(中位数年龄 20.4 个月,IQR 2.3-59.5)。131 名(85.1%)接受了至少一种肾毒素;32 名(20.8%)接受了≥3 种肾毒素。最常使用的药物是酮咯酸(n=74,48.1%)、阿司匹林(n=62,40.3%)、布洛芬(n=51,33.1%)、万古霉素(n=39,25.3%)、哌拉西林/他唑巴坦(n=35,22.7%)和依那普利(n=14,9.1%)。接受≥3 种肾毒素的儿童更常发生 AKI(62.5%比 50.8%);在调整混杂因素后,这并没有统计学意义(aRR=1.2,95%CI 0.9-1.7)。严重 AKI 在高肾毒素暴露组和无高肾毒素暴露组之间相似(21.9%比 19.7%,p=0.78)。
儿科 CHS 后肾毒素的使用很常见。虽然我们没有发现高肾毒素暴露与 AKI 之间存在关联,但这可能与该人群 AKI 的多因素性质有关。对于许多常见的肾毒素,存在毒性较小的药物,肾毒素暴露可能是 AKI 的一个可改变的危险因素。